Mounjaro FAQ: safety, doses and UK access

Whether Mounjaro is right for you is a decision for a qualified prescriber, not a self-assessment. The UK weight-management licence is for adults aged 18 and over with a body-mass index (BMI) of 30 kg/m² or above (obesity), or 27 to 30 kg/m² (overweight) with at least one weight-related health problem such as prediabetes, high blood pressure, abnormal blood fats or cardiovascular disease — used alongside a reduced-calorie diet and more physical activity^[1]. Some people cannot take it at all (see the next question). A prescriber checks your BMI, medical history and other medicines before deciding.

Mounjaro is a licensed UK medicine, not a grey-market product — but like all medicines it carries risks, which is why it is prescription-only. Its side effects are mostly gastrointestinal and usually mild to moderate^[3]. Some people should not use it: the UK product information contraindicates a serious allergy to tirzepatide or any ingredient^[2]. The US prescribing information goes further, contraindicating it in anyone with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)^[8]. That reflects a two-year rat study in which tirzepatide caused thyroid tumours; whether that applies to people is not known, but it is why a thyroid history matters^[8]. Prescribers also weigh cautions around pancreatitis, gallbladder disease and low blood sugar when it is combined with insulin or a sulfonylurea^[2][8].

The most common side effects are gastrointestinal — nausea, diarrhoea, constipation and vomiting — usually mild to moderate, more common as the dose goes up, and often easing over time^[3]. Nausea is the most frequent: in the 72-week SURMOUNT-1 trial it affected about 31% of people on the 15 mg dose, against roughly 10% on placebo^[3]. The slow, four-weekly dose increases exist to keep these effects manageable^[1]. Our Mounjaro side effects page sets out the fuller picture and the label warnings.

Not without a prescription. Mounjaro is a prescription-only medicine, so the only legal route is a consultation with a qualified prescriber who decides it is appropriate, with the medicine then dispensed against that prescription^[1]; a legitimate online service will always assess you first. Any website, social-media account, gym or salon offering to sell Mounjaro without an assessment is breaking the law, and what they supply may be fake, contaminated or the wrong dose. The government's Fake Meds campaign explains how to check a seller at fakemeds.campaign.gov.uk^[9].

NHS access is real, but narrow and phased. NICE recommended tirzepatide for managing overweight and obesity in technology appraisal TA1026, with final guidance published on 23 December 2024^[6]. Because so many people are eligible, NHS England is rolling it out in stages through primary care, starting on 23 June 2025 and prioritising those with the highest clinical need first — an eligible group of around 220,000 people is expected over the first three years^[7]. NHS patients also receive dietary and physical-activity support alongside the medicine^[7]. So being eligible on paper does not mean you can get it on the NHS straight away.

They are different medicines. Mounjaro is tirzepatide, which acts on two gut-hormone receptors at once — GIP and GLP-1 — while Wegovy is semaglutide, which acts on the GLP-1 receptor alone^[11]. Both are once-weekly injections used alongside diet and activity. The clearest head-to-head evidence in our sources is SURPASS-2, a type 2 diabetes trial in which tirzepatide produced greater weight loss than semaglutide 1 mg — about 7.6 kg (5 mg), 9.3 kg (10 mg) and 11.2 kg (15 mg) versus 5.7 kg^[5]. Note that trial used the diabetes dose of semaglutide, not the higher weight-loss dose, so it is not a direct Mounjaro-versus-Wegovy comparison. Which medicine suits you is a prescriber's judgement, not a league table.

The trial weight-loss figures describe the effect while people are taking the medicine — the SURMOUNT-1 results are an "on-treatment" (efficacy estimand) measure^[3]. Mounjaro works partly by reducing appetite, so if it is stopped, that appetite effect wears off and weight can return unless diet, activity and other changes are in place to hold it. That is one reason the medicine is licensed for use alongside a reduced-calorie diet and increased activity rather than on its own^[1], and why stopping is a conversation to have with your prescriber.

The UK sources we cite do not set a specific alcohol limit for Mounjaro, so we will not invent one. The authority on this is the patient information leaflet, together with your prescriber or pharmacist. As a general point, drinking can add to the nausea and stomach upset that are the most common side effects^[3], and it affects blood sugar — which matters more if you also take insulin or a sulfonylurea, where low blood sugar is a recognised risk^[2][8]. If in doubt, ask your pharmacist.

There is no blanket "do not drive" instruction for Mounjaro in the sources here. The main driving-relevant risk the labelling flags is low blood sugar (hypoglycaemia), mainly a concern when Mounjaro is combined with insulin or a sulfonylurea — a prescriber may reduce those doses to manage it^[2][8]. Feeling sick or unwell, especially in the first weeks or after a dose increase, could also affect your driving. The patient information leaflet is the authority, and you should not drive if you feel impaired.

Mounjaro is not a medicine to take when pregnant, trying to conceive or breastfeeding without a prescriber's guidance — this is a conversation to have before starting. UK product information also carries advice about contraception: according to the manufacturer's information, tirzepatide may make oral (tablet) contraceptives less reliable because it slows stomach emptying, and women using the pill are advised to add a barrier method or switch to a non-oral contraceptive for a time after starting and after each dose increase^[2]. If you are pregnant, might be, or are planning a pregnancy, tell your prescriber.

Mounjaro comes in six fixed strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — each a 0.6 mL injection under the skin^[2]. Nobody starts at the top: treatment begins at 2.5 mg once weekly for four weeks (a starter dose to settle the stomach, not to drive weight loss), then moves to 5 mg, after which it can rise in 2.5 mg steps no more often than every four weeks, up to a maximum of 15 mg, as tolerated and as the prescriber directs^[1][2]. You can inject on any day of the week, with or without food, rotating between the abdomen, thigh or upper arm^[2]. Our Mounjaro dosage page walks through the full ladder.

In SURMOUNT-1, a 72-week trial of 2,539 adults with obesity (or overweight plus a weight-related condition) who did not have type 2 diabetes, average weight loss was about 16.0% at 5 mg, 21.4% at 10 mg and 22.5% at 15 mg, versus 2.4% on placebo^[3]. At 15 mg that was roughly 24 kg^[4]. About 96% of people on 15 mg lost at least 5% of their body weight and 39.7% lost a quarter or more, against 0.3% on placebo^[4]. These are trial averages alongside diet and activity; individual results vary, and the figures describe weight loss while on treatment.

Tirzepatide is a single molecule that switches on two incretin receptors at once — GIP and GLP-1 — which is why it is sometimes called a "twincretin" or dual GIP/GLP-1 receptor agonist^[11]. Between them, those receptors help the pancreas release insulin when blood sugar is high, slow how quickly the stomach empties, and reduce appetite and food intake^[3]. The appetite effect is the one most people notice, and — alongside diet and activity — it is what leads to weight loss. Our what is Mounjaro overview goes deeper into the science and the licence.